American Diversified Holdings Corp. (OTC Pink: ADHC) operates as a diversified holding company that focuses on executive management, corporate governance, administrative support, financial advice, funding introductions and more to niche micro-cap private and public companies. Shares of the diversified consulting company soared 69% during trading on Thursday, May 3, 2018. Over the past month, American Diversified Holdings Corp. has seen average daily volume of 8.73 million shares. However, volume of 53.75 million shares or dollar volume of $473,000, exchanged hand during Thursday’s trading.
Shares of American Diversified Holdings Corp. surged today after the company announced that it has contracted China-based medical products manufacturer, Hubei Boshi Medical Instrumentation Co, Ltd. Specifically, American Diversified Holdings Corp. has entered into a design, manufacturing, and private labeling relationship and agreement with Hubei Boshi. Sample products have already been ordered and will be delivered to Brazos Biomedical, LLC for further assessment and testing. The initial focus of the relationship with be the develop the TENS migraine/headache apparatus. Here is the full press release detailing of the new Chinese business relationship:
American Diversified Holdings Corp. Press Release:
DEL MAR, Calif., May 3, 2018 /PRNewswire/ — American Diversified Holdings Corporation (OTC: ADHC) announced today that is has entered into a design, manufacturing and private labeling relationship with mainland China based medical products company Hubei Boshi Medical Instrumentation Co, Ltd.
Sample products have been ordered which will be sent to the Brazos Biomedical, LLC. Scientific Advisory Board Chairman (SAB), Dr. Iaonnis Skaribas, MD for assessment and testing. Additional design work will be coordinated between the Hubei Boshi manufacturing technical team and the Scientific Staff at Brazos Biomedical.
In addition to the TENS headache apparatus Hubei Boshi offers numerous other product lines including TENS based therapeutic devices, laser devices and other medical testing devices. The Brazos team will be assessing Hubei Boshi’s line of products to determine if we can expand the list of products to be developed for the US medical market.
ADHC has recently announced an agreement to Acquire Brazos Biomedical, LLC a Houston,TX, based medical device company currently developing the “AURACIS™” TENS based non opioid Migraine treatment device.
ABOUT TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS)
TENS is a therapy that uses low voltage electrical current for pain relief. The electricity produced by the TENS device stimulates the nerves and sends signals to the brain that block normal pain signals and produce natural pain killers called endorphins. TENS therapy is growing in acceptance by the patient and medical community as an alternative to opioid based treatments that have many negative side effects.
Shareholders will be updated on more developments in the near future as ADHC continues to progress.
For more information: www.brazosbio.com
About American Diversified Holdings Corporation
ADHC is a holding company that provides executive management, corporate governance, administrative support, financial advice, and introductions to capital sources to various micro-cap private and public companies that have proven revenues and business models.
About Brazos Biomedical, LLC
Brazos Biomedical is a biomedical device development company utilizing electrostimulation for pain management to improve patient outcomes through creative innovation with a core competency in the migraine and headache pain space.
This press release contains forward-looking statements pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements include risks and uncertainties that may cause the Company’s plans to change and are in no way intended to guarantee that the Company will be successful in executing its plans. American Diversified Holdings (ADHC) common stock currently trades on the over-the-counter under the symbol ADHC. This press release in no way constitutes any recommendation regarding the securities of ADHC or its affiliates. Any person reading this press release is advised that this release should be considered in the light of all facts and circumstances regarding the business and financial condition and prospects of ADHC, and no reference has been made that this release contains all information.
